+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B , AMB lipid formulations , or azoles



Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B , AMB lipid formulations , or azoles



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 371




(PDF emailed within 1 workday: $29.90)

Accession: 035349974

Download citation: RISBibTeXText


Related references

Update of the multicenter noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents Analysis of 90 patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 388, 2002

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107(12): 2888-2897, 2006

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clinical Infectious Diseases 39(11): 1563-1571, 2004

Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. Yearbook of Pulmonary Disease 2006: 318-320, 2006

An open non-comparative multicenter study to evaluate efficacy and safety of Posaconazole in the treatment of invasive fungal infections refractory to or intolerant to standard therapy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 372, 2000

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22(3): 496-503, 2007

Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. European Journal of Haematology 73(1): 50-55, 2004

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrobial Agents and ChemoTherapy 48(12): 4808-4812, 2004

An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 85(6): 644-651, 2012

Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Therapeutics and Clinical Risk Management 4(6): 1285-1294, 2009

An Open-Label, Noncomparative, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx Gel as a Bulking Agent for the Treatment of Fecal Incontinence. Gastroenterology Research and Practice 2010: 467136-467136, 2011

Efficacy of Voriconazole and Caspofungin after failure of Amphotericin B in a neutropenic patient with refractory acute myeloblastic leukemia and pulmonary aspergillosis. Blood 102(11): 231b, November 16, 2003

Efficacy and toxicity of the caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematologic malignancies. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 416, 2002

Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis. Journal of Infection and ChemoTherapy 21(6): 421-426, 2016

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study. Therapeutic Advances in Gastroenterology 11: 1756283x18756260-1756283x18756260, 2018